News

It's another step in Eli Lilly's quest to cement its lead in the chronic weight management market.

From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.

BRK.B, LLY and WMT headline top analyst reports, highlighting business strengths, growth drivers and key risks shaping their outlooks.

Competition is intensifying after WeightWatchers' Med+ program became available through LillyDirect.

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 6.3% in the afternoon session after the company announced its Weight Watchers Med+ program is now accessible through Eli Lilly's digital healthcare platform, LillyDirect.

Eli Lilly reported positive Phase 1b data for VERVE-102, a gene-editing cardiovascular therapy, raising fresh competitive pressure on CRISPR Therapeutics' CTX310 program. CRISPR Therapeutics (NasdaqGM:CRSP) is broadening beyond gene editing with the acquisition of CTX611, a phase 2 siRNA therapy targeting blood clotting. These developments arrive as large pharma and specialist biotech companies increase focus on genetic and RNA-based approaches to cardiovascular disease. For you as an...

Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.

Dow Jones futures fell slightly after hours, along with S&P 500 futures and Nasdaq futures. The May jobs report is on tap before Friday's open. The stock market saw the Dow Jones jump to a record high, aided by lower oil prices and Treasury yields.

Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.

Berkshire Hathaway, Eli Lilly and Walmart headline new analyst reports, highlighting growth drivers, opportunities and key risks shaping their outlooks.

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2%

Broadcom’s weak AI-chip guidance rattled semiconductors and raised questions about tech valuations today, June 4, 2026.

Eli Lilly stock is Thursday's IBD Stock Of The Day as the weight-loss behemoth deepens its focus on gene editing, vaccines and cancer.

WW International (NASDAQ:WW) has integrated its Weight Watchers Med+ offering with Eli Lilly’s (NYSE:LLY) LillyDirect healthcare platform, broadening access to its clinical weight management services for patients using or considering prescription obesity treatments. The collaboration connects LillyDirect users with Weight Watchers’ program, which combines GLP-1 medications with behavioral, nutritional and lifestyle support.

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

The company cited uncertainty surrounding proposed healthcare and drug-pricing reforms.

US equity futures were mixed pre-bell Thursday as traders watched tech giant Broadcom's (AVGO) stock

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

The shares are up more than 13% this year, and the pharmaceutical company has several other factors that could drive its stock higher.

Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines.

Eli Lilly is far from a one-trick pony.

Broadcom and CrowdStrike fell late on earnings. The SpaceX IPO price target and size have been set with the offering next week.

Drugmaker expands genetic medicine push with Ascidian partnership targeting rare kidney diseases.

Eli Lilly (NYSE:LLY) reported Phase 3 LIBRETTO-432 data showing Retevmo (selpercatinib) cut the risk of recurrence or death in early-stage RET fusion-positive non-small cell lung cancer. The results position Retevmo as a potential new adjuvant standard of care for this genetically defined group of lung cancer patients. Separately, Lilly released encouraging first-in-human data for VERVE-102, a gene-editing therapy targeting cardiovascular disease. Eli Lilly enters this news cycle with a...

Can any company pose a serious challenge to Eli Lilly in the weight-loss market?

Eli Lilly and Co. announced separate licensing and research agreements with South Korea-based Hanmi Pharm and China-based Haisco Pharmaceutical Group, expanding its access to new drug candidates and discovery programs. The deals come as investors also evaluate positive Phase 3...

SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.

Over recent months, a striking pattern has emerged: major capital allocators are positioning around AI-driven biology and longevity. According to a Polymarket post on X, Coinbase (NASDAQ:COIN) founder Brian Armstrong’s longevity startup NewLimit has tripled in value to $3.1 billion. That post sparked a viral reply thread from podcast host Mgoes (@m_goes_distance), cataloging billionaire and ... Move Over AI: Jeff Bezos and NVIDIA Are Quietly Backing a New Breakthrough Industry

Eli Lilly (NYSE:LLY) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion. Mounjaro and Zepbound combined for $12.8 billion in Q1 alone. Yet shares are up just 1.11% year to date, sitting at $1,082.92. Can LLY reach $1,500 a share by 2028? Why Lilly Shares Have ... Where Will Eli Lilly Stock be In 2028?

Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach.